ONCOLOGY Vol 25 No 14 | Oncology

In-Transit Melanoma: An Individualized Approach

December 15, 2011

The management of in-transit metastases is challenging, since the treatments and extent of disease vary greatly based on the number, depth, location, and distribution of lesions, and on their biological behavior.

Contemporary Management of Locally Invasive Bladder Cancer

December 16, 2011

Muscle-invasive bladder cancer is an aggressive and potentially lethal disease. Integration of multimodal therapies, improved surgical techniques, and utilization of targeted agents has tremendously improved outcomes.

Bladder Cancer Treatment: Optimize, Don't Compromise

December 16, 2011

Patient selection based on a much more comprehensive biologic assessment of both host and tumor is likely the key to further advances in the treatment of all bladder cancer patients. Until such time, there can be no compromise in the careful application of the rigorous therapy required to optimize outcomes.

The Year in Oncology: Breakthroughs and Controversies

December 15, 2011

The past year in oncology was highlighted by the continuation of breakthroughs in targeted therapies-with new treatments receiving US Food and Drug Administration (FDA) approval for non–small-cell lung cancer (NSCLC), lymphoma, and melanoma.

Individualized Local Treatment Strategies for In-Transit Melanoma

December 15, 2011

For localized in-transit disease, less is more, with local destruction, excision, and intralesional therapy being the cornerstones of treatment. If local therapies fail or if distant disease arises, isolated limb perfusion and systemic therapy remain effective options.

Transanal Excision of Rectal Cancer: A Work in Progress

December 15, 2011

The exact role of combined-modality therapy and TAE of rectal cancer remains to be defined. Certainly the stakes are high, as studies have shown that the recurrence of locally excised rectal cancer is associated with worse long-term survival outcomes.

Green Tea (Camellia sinensis)

December 16, 2011

The active constituent of green tea extract is EGCG, which accounts for 40% of its total polyphenol content. Regular consumption of green tea may reduce the risk of hypertension and positively affect mood.

25 Years Later: Endangered Species or Successful Evolution?

December 16, 2011

While ONCOLOGY has continued to evolve along with the field of oncology-for example, it now addresses critical issues of science and socioeconomics-it has remained true to the founding principles. Perhaps largely for this reason, the journal continues to be widely read across the entire oncology community.

The “Episode-of-Care” Payment Model: One Practice’s Experience

December 15, 2011

The episode-of-care project is the first program in which a payer has partnered with the oncology community to reduce costs while paying for the demanding and complex cognitive work of the medical oncologist. The episode-of-care payment system seems to be working smoothly and we have not experienced the same erosion of our income that we have seen with other payers.

SABCS: Dramatic CLEOPATRA Findings Support Addition of Pertuzumab to Regimen for HER2-Positive Metastatic Breast Cancer

December 08, 2011

Addition of pertuzumab to a standard chemotherapy combination of trastuzumab and docetaxel led to a 38% reduction in risk of disease worsening or death in patients with HER2-positive metastatic breast cancer, reported investigators from the randomized, double-blind, placebo-controlled phase III CLEOPATRA study.

Light-Induced, Specific Killing of Cancer Cells

November 07, 2011

Researchers have developed a novel way to molecularly target and kill cancer cells, called photoimmunotherapy. The method uses a monoclonal antibody against the epidermal growth factor coupled to a near-infrared dye. The result is a target-specific photosensitizer that causes specific cell death of cells bound by the antibody when NIR light is applied.

Chronicling Strides in Understanding and Managing Rectal Cancer

December 15, 2011

Advances in the treatment of rectal cancer, such as TME and CMT, have lengthened survival time and enhanced the quality of life. However, radiation therapy may have a negative impact on quality of life, especially in males. Future research needs to focus not only on survival but also on postoperative quality of life.

Managing CRPC: Improving Symptoms, Survival, or Both?

December 16, 2011

In addition to endeavors to develop new therapeutics, we should anticipate and prioritize studies that will address questions regarding the efficacy of combination therapy, timing and sequencing strategies, and the development of predictive markers to individualize and optimize therapy.

Are We Trumping Bone Disease in Prostate Cancer?

December 16, 2011

We are seeing a new era in drug development with the identification of novel intra- and extracellular targets to which therapies are being directed. Perhaps more exciting is learning how to optimize standard therapies in combination with biologic agents and radiopharmaceuticals in order to target multiple pathways in prostate cancer growth. Stay tuned!

Challenges in the Modern Treatment of Muscle-Invasive Bladder Cancer

December 16, 2011

Still missing in our treatment of bladder cancer are the tools to accurately predict response to a specific therapy, whether it be chemotherapy, radiation, or transurethral resection alone. Once we have these tools, we will be well on our way to applying a more intelligent, true personalized medicine approach to the treatment of this disease.